Obsidian Therapeutics Inc OBX

$13.86 +4.26 (44.43%)

Valuation

Market cap
856,483,000
Revenue TTM
$0
Net income TTM
$-100,610,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
2,092,100
Avg volume
533,600
Day's range
$9.71 – $14.77
Shares out
61,773,000
Stochastic %K
68%
Beta
—
Analysts
Strong Buy
Price target
$37.00

Price

Company profile

Obsidian Therapeutics, Inc. operates as a clinical-stage biotechnology company developing engineered cell and gene therapies. The company is developing investigational therapies, including OBX-115, which is being evaluated in clinical trials for advanced solid tumors, advanced melanoma, and relapsed refractory non-small cell lung cancer. It utilizes a proprietary Cytodriver technology platform designed to regulate pr...

Show more

Obsidian Therapeutics, Inc. operates as a clinical-stage biotechnology company developing engineered cell and gene therapies. The company is developing investigational therapies, including OBX-115, which is being evaluated in clinical trials for advanced solid tumors, advanced melanoma, and relapsed refractory non-small cell lung cancer. It utilizes a proprietary Cytodriver technology platform designed to regulate protein function using FDA-approved small-molecule drugs and is advancing tumor-infiltrating lymphocyte (TIL) cell therapies that leverage mbIL15 to enhance persistence, antitumor activity, and clinical safety. Access to investigational therapies is currently limited to participation in clinical trials, and the company collaborates with other organizations to apply its platform technology. The company was founded in 2015 and is based in Cambridge, Massachusetts.

Industry
Biotechnology
Sector
Healthcare
Phone
781 806 6245
Website
https://obsidiantx.com
Address
1030 Massachusetts Avenue, Cambridge, United States

Latest news

Stocktwits

topstockalerts Nov 8, 2:20 PM
Top Gainers PT2 $SKIN $SNT $OBX $KRMN $RCT
0 replies
BiotechCatalystCalendar Nov 8, 12:39 AM
🧬 6 readouts, 1 read. $IMCR $OBX $IOVA $MRK $SNY SITC human data span dual T-cell engagers, TIL therapies and off-the-shelf NK cells. I unpack the results, safety, treatment burden and what to watch next. First readout is free. https://biotechcatalystcalendar.substack.com/p/sitc-so-far #SITC26 #Biotech #Immunotherapy
0 replies
topstockalerts Nov 7, 2:44 PM
Top Gainers PT2 $SKIN $SNT $OBX $KRMN $RCT
0 replies
bungbob Nov 7, 1:37 AM
$IOVA this stocks given me real money, fake money, and in the beginning it was losing me money. This company will be the platform hub of all TIL therapies, I see it being prepared in the future to buyout $OBX who is a brand new company with no overhead structure or ATCs that IOVA has the paved way for. I like the stock.
1 replies
StockScanners Nov 7, 12:58 AM
$OBX keep watch if this holds above 12.80
0 replies
topstockalerts Nov 6, 10:38 PM
Top Gainers PT2 $SKIN $CDT $SNT $OBX $GIBO
0 replies
MattySh Nov 6, 10:35 PM
$IOVA $OBX Had my quarterly scans and met with my onc doc yesterday. The good news is no progression! Yay! We discussed next steps if for some reason there is progression in my future. Two neck dissections, 56 gray of radiation and after IPI/NIVO induced acute kidney injury, and a failed TIl (Amtagvi) manufacturing attempt I am somehow kicking the can down the road. We discussed what treatment options there would be, and he was not as gung ho as he used to be for Amtagvi due to the toxicity which is tough on people. He did mention the OBX-115 trial and would lean towards that if needed. He favors ACZ versus IL-2 for the kicker. I am over invested in IOVA getting in at sub $3 and was going to pare that position a bit and invest in OBX. I should have done that in the parking garage before the drive home, as now it appears that I am a day late as usual. Hopefully IOVA will see a buyout and/or their sBLA sooner rather than later. Congrats to OBX for good news at SITC.
3 replies
topstockalerts Nov 6, 8:46 PM
Top Gainers $SDA $GOGO $STAK $OBX $SKIN
0 replies